MannKind Corporation announces six-month results from phase 3 INHALE-1 of Afrezza inhalation powder in children and adolescents: Danbury, Connecticut Wednesday, December 18, 2024, ...

INHALE-1 is a 26-week, open-label clinical trial that randomized 230 subjects aged 4-17 years with type 1 or type 2 diabetes to either inhaled pre-meal insulin or multiple daily injections (MDI) of ...

MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior t ...

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...

Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.